Vericel Q4 Earnings Exceed Expectations with Strong Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy VCEL?
Source: seekingalpha
- Strong Earnings Report: Vericel's Q4 GAAP EPS of $0.45 beats expectations by $0.06, indicating a sustained enhancement in profitability and reflecting the company's competitive position in the market.
- Significant Revenue Growth: The total revenue reached $92.92 million, representing a 23.2% year-over-year increase and surpassing market expectations by $0.26 million, showcasing Vericel's success in product demand and market expansion.
- MACI Revenue Performance: MACI® net revenue grew by 23% to $84.1 million, further solidifying its market position in regenerative medicine and is expected to drive future revenue growth.
- Future Financial Guidance: Vericel anticipates total revenue between $316 million and $326 million for 2026, with MACI revenue projected between $280 million and $286 million, demonstrating the company's confidence and strategic planning for future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VCEL
Wall Street analysts forecast VCEL stock price to rise
5 Analyst Rating
4 Buy
1 Hold
0 Sell
Strong Buy
Current: 34.390
Low
55.00
Averages
57.67
High
60.00
Current: 34.390
Low
55.00
Averages
57.67
High
60.00
About VCEL
Vericel Corporation is a fully-integrated, commercial-stage biopharmaceutical company. The Company is a provider of advanced therapies for the sports medicine and severe burn care markets. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full-thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for the removal of eschar in adult and pediatric patients with deep partial thickness and/or full-thickness thermal burns.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Vericel Receives Approval for MACI Commercial Production
- Regulatory Milestone: Vericel Corporation has received FDA approval to commence commercial manufacturing of MACI® at its state-of-the-art facility in Burlington, Massachusetts, marking a significant achievement in complex cell therapy manufacturing, with production expected to start in Q2 2026.
- Capacity Expansion: This approval enables Vericel to increase production capacity for its restorative cartilage repair product to meet rising market demand, further solidifying its leadership position in the sports medicine and severe burn care markets.
- Supply Chain Enhancement: The new facility's operational launch will strengthen the company's supply chain capabilities, supporting its mission to deliver innovative, high-quality therapies to patients while laying a foundation for long-term value creation for shareholders.
- International Market Potential: With the commercialization of MACI, Vericel plans to expand its reach into markets outside the U.S., further broadening its global business and seizing growth opportunities in international markets.
See More
Vericel Corporation to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Vericel Corporation will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, and at the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026, showcasing its advanced therapies in sports medicine and severe burn care.
- Webcast Availability: The company will provide a webcast of the presentations on its Investor Relations section of the website, ensuring that investors can access real-time updates, thereby enhancing transparency and investor confidence.
- Product Portfolio Strength: Vericel markets three key products in the U.S., including MACI® and Epicel®, which combine innovations in biology with medical technologies aimed at repairing injuries and improving patient quality of life, demonstrating the company's competitiveness in the industry.
- Market Positioning: As a leader in the sports medicine and severe burn care markets, Vericel is committed to meeting patient needs and driving long-term growth through its unique cell therapies and specialty biologics, further solidifying its market position.
See More
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
Vericel Reports Significant Earnings Growth in Q4
- Earnings Performance: Vericel Corporation reported a net income of $23.24 million for Q4, translating to an earnings per share (EPS) of $0.45, which marks a significant increase from last year's $19.81 million and $0.38 EPS, indicating enhanced competitiveness in the market.
- Significant Revenue Growth: The company's revenue surged by 23.3% year-over-year to $92.92 million, up from $75.38 million last year, demonstrating strong product demand and an expanding market share.
- Improved Financial Health: With both revenue and earnings on the rise, Vericel's financial health has markedly improved, enhancing its investment appeal in the biopharmaceutical sector and providing stronger funding support for future R&D and market expansion.
- Optimistic Market Outlook: The performance boost not only reflects current market demand but also lays a foundation for future growth, likely attracting more investor attention and further driving stock price appreciation.
See More
Vericel Q4 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Vericel's Q4 GAAP EPS of $0.45 beats expectations by $0.06, indicating a sustained enhancement in profitability and reflecting the company's competitive position in the market.
- Significant Revenue Growth: The total revenue reached $92.92 million, representing a 23.2% year-over-year increase and surpassing market expectations by $0.26 million, showcasing Vericel's success in product demand and market expansion.
- MACI Revenue Performance: MACI® net revenue grew by 23% to $84.1 million, further solidifying its market position in regenerative medicine and is expected to drive future revenue growth.
- Future Financial Guidance: Vericel anticipates total revenue between $316 million and $326 million for 2026, with MACI revenue projected between $280 million and $286 million, demonstrating the company's confidence and strategic planning for future growth.
See More
Vericel Scheduled to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Vericel is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of $0.38, indicating stable profitability compared to last year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $92.66 million, reflecting a 22.9% year-over-year increase, showcasing the company's growth potential and rising product demand despite competitive pressures in the industry.
- Estimate Revision Dynamics: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates experienced one upward revision, indicating analysts' cautious outlook on the company's future performance, which may affect investor confidence.
- Long-Term Revenue Outlook: Vericel expects to achieve $276 million in revenue by 2025, suggesting that despite short-term challenges, the company remains confident in its strategic planning and future growth prospects.
See More
Vericel Receives Approval for MACI Commercial Production
- Regulatory Milestone: Vericel Corporation has received FDA approval to commence commercial manufacturing of MACI® at its state-of-the-art facility in Burlington, Massachusetts, marking a significant achievement in complex cell therapy manufacturing, with production expected to start in Q2 2026.
- Capacity Expansion: This approval enables Vericel to increase production capacity for its restorative cartilage repair product to meet rising market demand, further solidifying its leadership position in the sports medicine and severe burn care markets.
- Supply Chain Enhancement: The new facility's operational launch will strengthen the company's supply chain capabilities, supporting its mission to deliver innovative, high-quality therapies to patients while laying a foundation for long-term value creation for shareholders.
- International Market Potential: With the commercialization of MACI, Vericel plans to expand its reach into markets outside the U.S., further broadening its global business and seizing growth opportunities in international markets.
See More
Vericel Corporation to Present at Upcoming Investor Conferences
- Investor Conference Schedule: Vericel Corporation will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, and at the Leerink Partners 2026 Global Healthcare Conference on March 10, 2026, showcasing its advanced therapies in sports medicine and severe burn care.
- Webcast Availability: The company will provide a webcast of the presentations on its Investor Relations section of the website, ensuring that investors can access real-time updates, thereby enhancing transparency and investor confidence.
- Product Portfolio Strength: Vericel markets three key products in the U.S., including MACI® and Epicel®, which combine innovations in biology with medical technologies aimed at repairing injuries and improving patient quality of life, demonstrating the company's competitiveness in the industry.
- Market Positioning: As a leader in the sports medicine and severe burn care markets, Vericel is committed to meeting patient needs and driving long-term growth through its unique cell therapies and specialty biologics, further solidifying its market position.
See More
Vericel Corporation Reports Strong Q4 2025 Earnings with Record Revenue Growth
- Record Financial Performance: Vericel Corporation reported fourth quarter total revenue of $92.9 million, reflecting a 23% year-over-year growth, with full-year revenue reaching $276.3 million, exceeding expectations and showcasing the company's strong market performance and profitability.
- Significant MACI Sales Growth: The MACI product line generated over $84.1 million in revenue during Q4, marking a 23% increase compared to the previous year and a 51% sequential growth, indicating substantial progress in expanding market share and product acceptance.
- Strategic Investments and Expansion: The company plans to continue expanding its MACI sales force in 2026 while advancing the MACI Ankle clinical study and international market expansion, with projected MACI revenue guidance of $280 million to $286 million for the full year, reflecting confidence in future growth.
- Cash Flow and Financial Health: By the end of 2025, the company reported approximately $200 million in cash and investments with no debt, alongside an operating cash flow of $52 million for the year, demonstrating robust financial management and operational efficiency.
See More
Vericel Reports Significant Earnings Growth in Q4
- Earnings Performance: Vericel Corporation reported a net income of $23.24 million for Q4, translating to an earnings per share (EPS) of $0.45, which marks a significant increase from last year's $19.81 million and $0.38 EPS, indicating enhanced competitiveness in the market.
- Significant Revenue Growth: The company's revenue surged by 23.3% year-over-year to $92.92 million, up from $75.38 million last year, demonstrating strong product demand and an expanding market share.
- Improved Financial Health: With both revenue and earnings on the rise, Vericel's financial health has markedly improved, enhancing its investment appeal in the biopharmaceutical sector and providing stronger funding support for future R&D and market expansion.
- Optimistic Market Outlook: The performance boost not only reflects current market demand but also lays a foundation for future growth, likely attracting more investor attention and further driving stock price appreciation.
See More
Vericel Q4 Earnings Exceed Expectations with Strong Revenue Growth
- Strong Earnings Report: Vericel's Q4 GAAP EPS of $0.45 beats expectations by $0.06, indicating a sustained enhancement in profitability and reflecting the company's competitive position in the market.
- Significant Revenue Growth: The total revenue reached $92.92 million, representing a 23.2% year-over-year increase and surpassing market expectations by $0.26 million, showcasing Vericel's success in product demand and market expansion.
- MACI Revenue Performance: MACI® net revenue grew by 23% to $84.1 million, further solidifying its market position in regenerative medicine and is expected to drive future revenue growth.
- Future Financial Guidance: Vericel anticipates total revenue between $316 million and $326 million for 2026, with MACI revenue projected between $280 million and $286 million, demonstrating the company's confidence and strategic planning for future growth.
See More
Vericel Scheduled to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Vericel is set to release its Q4 earnings on February 26 before market open, with a consensus EPS estimate of $0.38, indicating stable profitability compared to last year.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $92.66 million, reflecting a 22.9% year-over-year increase, showcasing the company's growth potential and rising product demand despite competitive pressures in the industry.
- Estimate Revision Dynamics: Over the past three months, EPS estimates have seen no upward revisions and one downward revision, while revenue estimates experienced one upward revision, indicating analysts' cautious outlook on the company's future performance, which may affect investor confidence.
- Long-Term Revenue Outlook: Vericel expects to achieve $276 million in revenue by 2025, suggesting that despite short-term challenges, the company remains confident in its strategic planning and future growth prospects.
See More
